About Us
Resolve Nanotherapeutics dedicated to creating a first-in-class broadly active RNA drug for severe acute bacterial infections and accompanying chronic complications
Our Goals
- Save lives during acute phase of an infection by preventing immune dysfunction and organ damage
- Prevent severe complications due to serious acute infections (hospital re-admission or death)
- Provide a safe and effective treatment option for physicians beyond antibiotics
Opportunity
Due to rising rates of antibiotic resistance, common infections are increasingly spiraling into life-threatening crises. A lack of new antibiotics in the drug development pipeline means that we are losing the race against bacterial infections, leaving an urgent gap in care for patients. Filling that gap could save millions of lives annually – and redefine a multi-billion market that remains largely underserved
01.
Global Infection Toll
Acute infections—pneumonia, peritonitis, febrile neutropenia — kill millions of people annually, making them one of the world’s leading causes of death. Most patients require hospitalization, and many deteriorate into intensive care. Mortality can reach 15–45 % within the first month. Survivors often endure repeat admissions, organ damage, cognitive fog, and bills exceeding $30,000.
02.
Antibiotics Losing Ground
These grim outcomes unfold despite widespread antibiotic use. Bacteria are evolving faster than antibiotic drug pipelines can replenish them. The WHO warns that within 15–20 years many current antibiotics will be completely ineffective. Without new treatment options, once-routine infections may become untreatable.
03.
Critical Care Gap
ICUs overflow and budgets strain as clinicians exhaust existing treatment options. When antibiotics falter, care teams have no reliable fallback and must rely on expensive and invasive supportive care procedures. Patients and families bear lifelong physical, cognitive, and financial burdens. A resistance-proof therapy would instantly redefine the standard of care.
04.
Vast Market Upside
Treatments for acute infections already cost tens of billions of dollars annually. Breakthrough modalities capable of circumventing resistance could capture a significant portion of that spend. First movers can also address chronic complications that can arise post-infection, currently without treatment. Rarely do humanitarian impact and compelling returns align so clearly.
Our Solution
Resolve Nanotherapeutics uses RNA delivered by lipid nanoparticle technology to rapidly amplify the body’s ability to clear bacterial toxins. This reduces the damaging inflammation associated with acute infections and improves survival by preventing serious complications such as organ damage. This host-focused strategy works on ALL types of bacteria regardless of antibiotic resistance profile and does not have a clear mechanism by which bacteria could evolve resistance.
Host-Focused Strategy
We have studied how the body naturally clears infections and amplify that defence. By dialling up the body’s toxin-clearance pathway, our therapy neutralises every bacterium—sensitive or resistant—without touching the microbe itself. With no direct pressure on pathogens, resistance cannot emerge. Broad-spectrum protection, zero resistance risk.
Genetic Validation Proof
People born with genetic mutations that "turn-on" this toxin-clearance pathway survive sepsis up to 25 % more often. Human genetics and animal studies converge on the same life-saving targets, giving us a uniquely de-risked starting point to develop RNA drugs. Nature has effectively run the first trial. We’re translating that proof into medicine.
Precise RNA Delivery
Clinically proven lipid nanoparticles deliver RNA straight into liver cells, switching target genes on or off within hours. This RNA delivery platform is highly programmable and easy to scale. A single i.v. dose can quickly and potently ramp up the toxin clearance pathway when patients need it most.
Our Technology
RNA-based therapeutics can be programmed to turn “on” or “off” any therapeutic target protein in the right cells in a rapid and clinically relevant timescale.
Natural Immunity
Our LNP‑RNA therapy switches "on" the body’s toxin‑clearing system. This amplifies the body's own innate defences and helps to flush bacterial toxins that accumulate during severe infection. Patients recover faster with less organ damage.
Broad Spectrum
By boosting the immune system of the host, not attacking microbes, our therapy works on every bacterial species, sensitive or resistant, addressing mixed ICU infections without driving new resistance.
Novel Druggability
Validated gene targets switch "on" or "off" within hours through plug‑and‑play LNP‑RNA, enabling the targeting of biological pathways that cannot be targeted by traditional small molecule approaches.
Novel · Broad Spectrum · Effective
Our host-focused LNP-RNA therapy has already cut mortality in resistant pneumonia models—showing how a single dose can outflank pathogenic bacteria and protect fragile lungs.
No obvious resistance development
Broad spectrum activity
Validated delivery
Proven scalability
Rapid development timeline
Minimal risk of side effects
An experienced world-leading team
A world-class team of critical care clinician researchers, drug development and delivery experts, and infectious disease microbiologists with 5 FDA approved drugs, more than 35 years of ICU leadership experience, and over 90 years of combined drug development expertise.Â
Our Sponsors
Resolve Nanotherapeutics stands at the intersection of an urgent medical need and a novel scientific approach. Our host-focused, LNP-RNA-powered platform targets a multi-billion dollar market, backed by genetics knowledge that de-risks the approach, that is primed for rapid development using LNP technology that can readily be scaled for global use.Â
Join us in transforming acute-infection patient care and capturing the value of a resistance-proof future.
Get Involved Today
Join us in making a difference. Your support helps drive breakthroughs in nanotherapeutics for those in need.